206 related articles for article (PubMed ID: 30541682)
1. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
García Díaz E; Ramírez Medina D; Morera Porras ÓM; Cabrera Mateos JL
Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):223-231. PubMed ID: 30541682
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III.
Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG;
Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490
[TBL] [Abstract][Full Text] [Related]
4. [Inertia and treatment compliance in patients with type 2 diabetes in primary care].
López-Simarro F; Brotons C; Moral I; Cols-Sagarra C; Selva A; Aguado-Jodar A; Miravet-Jiménez S
Med Clin (Barc); 2012 Apr; 138(9):377-84. PubMed ID: 22036458
[TBL] [Abstract][Full Text] [Related]
5. [Hypolipidemic and antihypertensive therapy in diabetic patients in the Czech Republic: notes on the VZP (General Health Insurance Company) Data].
Šnejdrlová M; Češka R; Janíčková-Žďárská D; Honěk P; Dušek P; Pavlík T; Kvapil M
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S30-7. PubMed ID: 26652963
[TBL] [Abstract][Full Text] [Related]
6. Main barriers in the management of dyslipidaemias: Intolerants.
Mostaza JM; Lahoz C
Clin Investig Arterioscler; 2021 May; 33 Suppl 1():40-45. PubMed ID: 33966812
[TBL] [Abstract][Full Text] [Related]
7. Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).
Bayram F; Sonmez A; Haymana C; Sabuncu T; Dizdar OS; Gurkan E; Carlioglu AK; Agbaht K; Ozdemir D; Demirci I; Barcin C; Salman S; Tetiker T; Balci MK; Kebapci N; Ersoy C; Yumuk V; Toth PP; Satman I;
Lipids Health Dis; 2020 Nov; 19(1):237. PubMed ID: 33176832
[TBL] [Abstract][Full Text] [Related]
8. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
9. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
[TBL] [Abstract][Full Text] [Related]
10. [A new approach to the treatment of dyslipidemia].
Kevelaitiene S; Slapikas R
Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
[TBL] [Abstract][Full Text] [Related]
11. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering drug prescriptions in a group of Colombian patients.
Gaviria-Mendoza A; Machado-Duque ME; Machado-Alba JE
Biomedica; 2019 Dec; 39(4):759-768. PubMed ID: 31860186
[TBL] [Abstract][Full Text] [Related]
13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
14. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
Kondo Y; Hamai J; Nezu U; Shigematsu E; Kamiko K; Yamazaki S; Yoshii T; Takahashi M; Takano T; Kawasaki S; Yamada M; Yamakawa T; Terauchi Y
Endocr J; 2014; 61(4):343-51. PubMed ID: 24452015
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
17. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
Karalis DG
Clin Cardiol; 2008 Jun; 31(6):241-8. PubMed ID: 17847038
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
20. [New indications and therapeutic objectives for dyslipidemia].
Maiques Galán A
Aten Primaria; 2006 Nov; 38(9):473-5. PubMed ID: 17194348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
